GT BIOPHARMA, INC. Stock Issued During Period, Value, Employee Benefit Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GT BIOPHARMA, INC. stock issued during period, value, employee benefit plan for the quarter ending 2023-03-31 was $507.00K, a 13.42% increase year-over-year.
- GT BIOPHARMA, INC. stock issued during period, value, employee benefit plan for the quarter ending 2022-03-31 was $447.00K.
- GT BIOPHARMA, INC. stock issued during period, value, employee benefit plan for fiscal 2023 was $267.00K, a 89.41% decline from fiscal 2022.
- GT BIOPHARMA, INC. stock issued during period, value, employee benefit plan for fiscal 2022 was $2.52M, a 85.15% decline from fiscal 2021.
- GT BIOPHARMA, INC. stock issued during period, value, employee benefit plan for fiscal 2021 was $16.98M.
| Period end | Stock Issued During Period, Value, Employee Benefit Plan 3 month | Stock Issued During Period, Value, Employee Benefit Plan 12 month |
|---|---|---|
| 2023-12-31 | $267.00K 10-K · filed 2024-03-26 | |
| 2023-03-31 | $507.00K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $2.52M 10-K · filed 2024-03-26 | |
| 2022-03-31 | $447.00K 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $16.98M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |